Inhibiting receptor tyrosine kinases is commonly achieved by two main strategies targeting either the intracellular kinase domain by low molecular weight compounds or...
![In vivo neurophysiological assessment of in silico predictions of neurotoxicity: Citronellal, 3,4-dichloro-1-butene, and benzyl bromoacetate](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
In vivo neurophysiological assessment of in silico predictions of neurotoxicity: Citronellal, 3,4-dichloro-1-butene, and benzyl bromoacetate
Neurotoxicants may be widespread in the environment and can produce serious health impacts in the human population.
![Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review
Esaxerenone is a selective, nonsteroidal, high-affinity mineralocorticoid receptor antagonist recently approved in Japan for the treatment of hypertension.
![Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
The emergence of SARS-CoV-2 variants of concern (VOCs) requires the development of next-generation biologics that are effective against a variety of strains of the virus.
![Post-Approval/Generics Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Post-Approval/Generics Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A
Q&A presented at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Post Approval: Generics Track – Assessing the Potential for Hepatotoxicity for Combination Therapy of Valproate (VPA) and CBD using Quantitative Systems Toxicology (QST)](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Post Approval: Generics Track – Assessing the Potential for Hepatotoxicity for Combination Therapy of Valproate (VPA) and CBD using Quantitative Systems Toxicology (QST)
Presented by Vinal Lakhani at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Clinical Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Clinical Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A
Q&A presented at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Clinical Track Poster Presentation: Count data model for Alzheimer disease progression MMSE score using MonolixSuite®](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Clinical Track Poster Presentation: Count data model for Alzheimer disease progression MMSE score using MonolixSuite®
Presented by Pauline Traynard at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Post-Approval/Generics Track Poster Presentation: Use of PBBM to Establish Dissolution Safe Space via IVIVR for Concor®](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Post-Approval/Generics Track Poster Presentation: Use of PBBM to Establish Dissolution Safe Space via IVIVR for Concor®
Presented by Joyce Macwan at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Post-Approval/Generics Track Poster Presentation: Relationship between Pimavanserin Exposure and QTc Interval in Patients with Schizophrenia: Modelling Analysis from Randomized, Double-Blind, Placebo-Controlled Studies](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Post-Approval/Generics Track Poster Presentation: Relationship between Pimavanserin Exposure and QTc Interval in Patients with Schizophrenia: Modelling Analysis from Randomized, Double-Blind, Placebo-Controlled Studies
Presented by Hannah Huang at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Post-Approval/Generics Track Poster Presentation: Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors. Possibilities, difficulties, and challenges](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Post-Approval/Generics Track Poster Presentation: Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors. Possibilities, difficulties, and challenges
Presented by Jonathan Chauvin at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Clinical Track Poster Presentation: Clinical Ocular Exposure Extrapolation Using PBPK Modeling & Simulation: Levofloxacin Solution Case Study](https://www.simulations-plus.com/wp-content/uploads/Clinical-Track-Poster-Presentation-1200x1080.jpg)
Clinical Track Poster Presentation: Clinical Ocular Exposure Extrapolation Using PBPK Modeling & Simulation: Levofloxacin Solution Case Study
Presented by Maxime LeMerdy at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Clinical Track: Yo-Yo Dieting Predicted to Contribute to Fibrosis Score Reductions in Untreated (Placebo) Cohorts](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Clinical Track: Yo-Yo Dieting Predicted to Contribute to Fibrosis Score Reductions in Untreated (Placebo) Cohorts
Presented by Lisl Shoda at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Post-Approval/Generics Track: Use of Exposure-Response Modeling to Support Regulatory Submission](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Post-Approval/Generics Track: Use of Exposure-Response Modeling to Support Regulatory Submission
Presented by Julie Passarell at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Pre-Clinical Track: Advancing Calcitonin Gene Related Peptide Receptor Antagonists Using QST Modeling to Characterize Next-in-Class Compounds Compared to the Hepatotoxic First in Class Telcagepant](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Pre-Clinical Track: Advancing Calcitonin Gene Related Peptide Receptor Antagonists Using QST Modeling to Characterize Next-in-Class Compounds Compared to the Hepatotoxic First in Class Telcagepant
Presented by Jeff Woodhead at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Women in Pharmaceutical Science](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Women in Pharmaceutical Science
Women in Science Session: Ways to Support Women in Science: Representation Matters!
![Regulatory Roundtable: Development and validation of PBBM/safe space from the regulatory perspective, a panel discussion](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Regulatory Roundtable: Development and validation of PBBM/safe space from the regulatory perspective, a panel discussion
This year we are happy to bring to you a hot topic suggested by last year's attendees. A regulatory roundtable on the Development and validation of PBBM and Safe Space from the regulatory perspective, is a one-hour panel discussion hosted by Sandra Suarez-Sharp and speakers from several regulatory agencies.
![Partner Solutions Concierge Program – Taking our Partnership to a Strategic Level](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Partner Solutions Concierge Program – Taking our Partnership to a Strategic Level
Presented by Josh Fohey at SLP MIDD+ Virtual Conference February 16th-17th, 2022
![Pre-Clinical Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A](https://www.simulations-plus.com/wp-content/uploads/Pre-clinical-track-pushing-the-boundaries-beyond-1200x1080.jpg)
Pre-Clinical Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A
Live Q&A with James Clary, Jeff Woodhead, Lara Clemens, Lisl Shoda, Maxime LeMerdy, Nader Hamzavi, Scott Q. Siler.
![Discovery Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Discovery Track: Pushing the Boundaries Beyond – NextGen Session Panel Discussion and Live Q&A
Live Q&A with David Miller, Marvin Waldman, Michael Lawless, Pankaj R. Daga, Phyo Phyo Kyaw Zin, and Robert Fraczkiewicz.